Sort
21,453 grants matching “tuberculosis”
Chemical Inhibitors to Define an Essential M. Tuberculosis Signaling Network
$1,214,907Robert N Husson · Boston Children'S Hospital · R01 · FY2014 · AI
Chemical Inhibitors to Define an Essential M. Tuberculosis Signaling Network
$1,214,907Robert N Husson · Boston Children'S Hospital · R01 · FY2015 · AI
Technology Core
$1,214,310John D. Aitchison · Seattle Children'S Hospital · U19 · FY2019 · AI
Second Generation Antibiotics from Ethambutol
$1,214,283Sequella, Inc. · UC1 · FY2000 · AI
India International Center for Excellence in Research
$1,213,940Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents
$1,213,831Charles A. Scanga · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI
Response Therapies for MDR-TB
$1,213,289Ian M Orme · Colorado State University · U01 · FY2007 · AI
Prevention of Substance Use in At-risk Students: A Family-centered Web Program
$1,213,204Elizabeth A Stormshak · University Of Oregon · R01 · FY2021 · DA
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
$1,212,985Richard H. Ebright · Rutgers, The State Univ Of N.J. · R01 · FY2014 · AI
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
$1,212,985Richard H. Ebright · Rutgers, The State Univ Of N.J. · R01 · FY2012 · AI
Hispanic Health Disparities Research Center
$1,212,299Elias Provencio-Vasquez · University Of Texas El Paso · P20 · FY2012 · MD
Predicting immune responses that correlate with protection against tuberculosis
$1,211,784Joanne L. Flynn · University Of Pittsburgh At Pittsburgh · R01 · FY2014 · HL
Clinical Core
$1,211,543Neel Rajnikant Gandhi · Emory University · U19 · FY2017 · AI
Thiolactomycin Acid Derivatives as Novel Antibacterials
$1,211,279Glaxosmithkline · UC1 · FY2000 · AI
NATURAL HISTORY OF HIV INFECTION IN INJECTION DRUG USERS
$1,211,172Johns Hopkins University · R37 · FY2001 · DA
Tuberculosis Surveillance, Prevention and Control, and Laboratory Upgrade
$1,211,074Maureen E Murphy · Ohio State Department Of Health · U52 · FY2010 · PS
Development of Inhaled CPZEN-45 For Tuberculosis Therapy
$1,210,721Diana M Severynse-Stevens · Research Triangle Institute · R01 · FY2022 · AI
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
$1,209,380Richard H. Ebright · Rutgers, The State Univ Of N.J. · R01 · FY2011 · AI
PS05-003 TUBERCULOSIS ELIMINATION AND LABORATORY
$1,209,082Nancy Baruch · Maryland State Department Of Health · U52 · FY2007 · PS
Bronchiectasis and chronic airway infection
$1,207,716Kenneth Olivier · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL
VANDERBILT ADULT AIDS CLINICAL TRIALS UNIT
$1,207,252Vanderbilt University · U01 · FY2002 · AI
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
$1,206,566Charles Testa · Curza Inc · R01 · FY2019 · AI
East Africa IEDEA Regional Consortium
$1,206,226Constantin T Yiannoutsos · Indiana University Indianapolis · U01 · FY2010 · AI
FY21 ITCA NARCH XI
$1,205,776Maria Dadgar · Inter Tribal Council Of Arizona, Inc. · S06 · FY2024 · GM
Optimization and Advanced Proof-of-Concept Studies of a Listeria-vectored Multi-Antigenic Vaccine against Tuberculosis
$1,205,608Marcus Aaron Horwitz · University Of California Los Angeles · R01 · FY2021 · AI